Disitamab Vedotin (RC48)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Disitamab Vedotin (RC48), covering 2023-05-08 to 2025-03-04. Get the full timeline:
Most recent: Clinical Trial Update: Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer. [NA]